Arbutus Biopharma
ABUS
ABUS
55 hedge funds and large institutions have $29.7M invested in Arbutus Biopharma in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 22 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
55% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 22
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Holders
55
Holding in Top 10
–
Calls
–
Puts
$8K
Top Buyers
| 1 | +$391K | |
| 2 | +$214K | |
| 3 | +$209K | |
| 4 |
WG
Winton Group
London,
United Kingdom
|
+$125K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$61K |
Top Sellers
| 1 | -$1.26M | |
| 2 | -$610K | |
| 3 | -$348K | |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$327K |
| 5 |
JPMorgan Chase & Co
New York
|
-$319K |